# Nuclide record netter-1 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/netter-1/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "netter-1", "NCT01578239" ;
  schema:name "NETTER-1"@en ;
  schema:description "The trial that made radioligand therapy a standard: a radioactive drug homing to the somatostatin receptor held midgut neuroendocrine tumours in check far longer than high-dose octreotide, and it underpins Lutathera's approvals."@en ;
  schema:url <https://nuclide.cc/trials/netter-1/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01578239>, <https://doi.org/10.1056/NEJMoa1607427> ;
  nuclide:status "positive" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/small-intestinal-net/> ;
  nuclide:technologies <https://nuclide.cc/technologies/prrt/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/lutathera/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/> .